Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine

Thompson, Hallie; Nichols, Laura; Santiago, Tania Gonzalez

doi:10.1136/bcr-2020-241293

Cited by 7 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To the best of our knowledge two further cases exist, occurring after the administration of the mRNA-1273 (Moderna) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines [36,37]. Cases related to the influenza [38], human papilloma virus [39], shingles [40], yellow fever [41], diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type B [42] vaccine have also been reported.…”

mentioning

confidence: 99%

Fixed drug eruptions – the common and novel culprits since 2000

McClatchy

Yap

Nirenberg

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryA fixed drug eruption (FDE) is a common cutaneous adverse drug reaction which occurs following administration of an offending drug. The aim of this review is to provide an update on the list of drugs causing FDE, with a focus on emerging drug culprits reported since the start of the century. Across published literature, triggers for FDE are widely varied. The most frequently implicated drugs include analgesics (nonsteroidal anti‐inflammatory drugs [NSAIDs] and paracetamol) and antibiotics. Co‐trimoxazole is perhaps the most well described single agent. Since the start of the century there have been over 200 drugs named in case reports on FDE. Newer, novel agents of note include cyclooxygenase‐2 specific inhibitors, fluconazole, and phosphodiesterase 5 inhibitors. Other implicated drugs include vaccines, such as various SARS‐CoV‐2 vaccines.Drugs incriminated in FDE vary based on the geographical region studied and prescribing patterns at a given time. Newer drugs continue to enter the market and are playing an increasing role in the field of FDE. Awareness of rarer culprits and emerging novel agents can help identify a trigger, allowing for prompt withdrawal of the causative agent, preventing recurrence.

show abstract

mentioning

confidence: 99%

Fixed drug eruptions – the common and novel culprits since 2000

McClatchy

Yap

Nirenberg

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…So far, HZ has only sporadically been reported after vaccination with RZV [30][31][32][33]. In two studies (ZOE-50 and ZOE-70) no increased incidence of HZ, herpes simplex or rash within 30 days after vaccination with RZV was observed compared with placebo (http://www.…”

Section: Discussionmentioning

confidence: 99%

Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020

Orru',

Bierbaum,

Enk

et al. 2023

Eurosurveillance

View full text Add to dashboard Cite

Background Shortly after the launch of a novel adjuvanted recombinant zoster vaccine (RZV), Shingrix, cases of suspected herpes zoster (HZ) or zoster-like skin reactions following immunisation were reported. Aim We aimed to investigate if these skin manifestations after administration of RZV could be HZ. Methods Between April and October 2020, general practitioners (GP) reporting a suspected case of HZ or zoster-like skin manifestation after RZV vaccination to the Paul-Ehrlich-Institut, the German national competent authority, were invited to participate in the study. The GP took a sample of the skin manifestation, photographed it and collected patient information on RZV vaccination and the suspected adverse event. We analysed all samples by PCR for varicella-zoster virus (VZV) and herpes-simplex virus (HSV) and genotyped VZV-positive samples. In addition, cases were independently assessed by two dermatologists. Results Eighty eligible cases were enrolled and 72 could be included in the analysis. Of the 72 cases, 45 were female, 33 were 60–69 years old, 32 had skin symptoms in the thoracic and 27 in the cervical dermatomes. Twenty-seven samples tested PCR positive for VZV (all genotyped as wild-type, WT), three for HSV-1 and five for HSV-2. Conclusion It may be difficult to distinguish HZ, without a PCR result, from other zoster-like manifestations. In this study, VZV-PCR positive dermatomal eruptions occurring in the first weeks after immunisation with RZV were due to WT VZV, which is not unexpected as HZ is a common disease against which the vaccine is unlikely to provide full protection at this time.

show abstract

“…Unseres Wissens gibt es zwei weite re Fälle, die nach Verabreichung der Impfstoffe mRNA1273 (Moderna) und ChAdOx1 nCoV19 (OxfordAstraZeneca) auftraten [36,37]. Fälle im Zusammenhang mit Impfstoffen gegen Influenza [38], humanes Papillomvirus [39], Gürtelro se [40], Gelbfieber [41], DiphtherieTetanusPertussis (azel lulär)inaktiviertes Poliovirus und Haemophilus influenzae Typ B [42] wurden ebenfalls berichtet.…”

Section: Gastrointestinales Systemunclassified

Fixes Arzneimittelexanthem – häufige und neue Auslöser seit dem Jahr 2000

McClatchy

Yap

Nirenberg

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Fixe Arzneimittelexantheme (FAE) sind häufige unerwünschte Arzneimittelreaktionen der Haut, die nach Verabreichung auslösender Medikamente auftreten. Ziel dieser Übersicht ist es, eine aktualisierte Auflistung der Medikamente vorzulegen, die ein FAE verursachen. Dabei liegt der Schwerpunkt auf neu in Erscheinung getretene Auslöser, die seit Beginn des Jahrhunderts dokumentiert wurden. Die veröffentlichten Auslöser von FAE sind sehr vielfältig. Zu den am häufigsten mit FAE in Verbindung gebrachten Medikamenten gehören Analgetika (nichtsteroidale Antirheumatika [NSAR] und Paracetamol) und Antibiotika. Der am besten beschriebene Einzelwirkstoff ist wohl Cotrimoxazol. Seit Beginn des Jahrhunderts wurden mehr als 200 Medikamente in Fallberichten zum FAE genannt. Bedeutende neuartige Wirkstoffe sind unter anderem Cyclooxygenase‐2‐spezifische Inhibitoren, Fluconazol und Phosphodiesterase‐5‐Hemmer. Weitere mit FAE in Verbindung gebrachte Medikamente sind Impfstoffe, zum Beispiel verschiedene Impfstoffe gegen SARS‐CoV‐2. Medikamente, die für ein FAE verantwortlich gemacht werden, unterscheiden sich nach geografischer Region und der Verschreibungsmuster zu bestimmten Zeitpunkten. Neuere Medikamente kommen weiterhin auf den Markt und spielen eine wachsende Rolle für FAE. Bewusstsein hinsichtlich seltenerer Auslöser und neu in Erscheinung tretender Wirkstoffe kann dabei helfen, Auslöser zu erkennen. Dies ermöglicht die unverzügliche Absetzung des verursachenden Wirkstoffs und kann damit ein Rezidiv verhindern.

show abstract

Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine

Cited by 7 publications

References 11 publications

Fixed drug eruptions – the common and novel culprits since 2000

Fixed drug eruptions – the common and novel culprits since 2000

Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020

Fixes Arzneimittelexanthem – häufige und neue Auslöser seit dem Jahr 2000

Contact Info

Product

Resources

About